NYSE · Healthcare · Drug Manufacturers - General · USA
Merck & Co Inc is a mega cap company (market value over $200 billion) in the Drug Manufacturers - General industry.
Merck & Co is a global healthcare company that delivers pharmaceutical and vaccine products through its Pharmaceutical segment, which serves hospitals, wholesalers, government agencies and managed care providers, and its Animal Health segment, which offers veterinary pharmaceuticals, vaccines, health management solutions and digitally connected identification and monitoring products for livestock and companion animals.
From its FY2025 annual report (Form 10-K)
Intrinsic value, DCF valuation, financial health and value investing analysis for the Merck & Co Inc stock.
Overvalued: intrinsic value $39.36 per share, market price $143.63, margin of safety -264.9% (as of 2026-10-19).
Discounting its cash flows at 11.0% (average of 3 methods) values the shares at $39.36; the price of $143.63 is 265% above that value, and 70% of that value comes from beyond year five.
Leak Score: 39/100 on 11 of 12 signals (On Watch).
17 more funds hold it; the full list is part of the paid plan.
All 21 Drug Manufacturers - General stocks
8 more in this industry show a wider margin of safety.
MRK is overvalued (as of the 2026-10-19 close). Discounting its cash flows at 11.0% (average of 3 methods) values the shares at $39.36; the price of $143.63 is 265% above that value, and 70% of that value comes from beyond year five.
$39.36 per share (as of the 2026-10-19 close), against a market price of $143.63. That is a margin of safety of -264.9%. The value is the average of the valuation methods that apply to this company, recomputed every night after the US close.
The price needs faster growth than we project for any company. It is betting on an exception. Yearly sales growth the price needs: 63.8%. Yearly sales growth it has sustained: 6.7%.
39 out of 100, which we rate "On Watch", on 11 of 12 value investing signals.